Codon Devices is a new biotechnology start-up that was recently profiled in Forbes Magazine. The company proposes to design bioengineering systems that will allow scientists to edit DNA sequences to create synthetic sequences for research and easier protein generation. Currently, molecular biology ressearch involves time consuming processes of cutting and ligating sequences together then transforming cells that will hopefully express the desired protein.
The founders recognize the challenge of their proposal but are optimistic about the potential of the technology, as are investors. One co-founder, Jay Keasling of the University of California, Berkeley, has recieved $42.6 million from the Bill & Melinda Gates Foundation via One World Health, to develop an anti-malarial medicine.
